114 related articles for article (PubMed ID: 34080646)
1. IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells.
Karakaş N; Stuckey D; Revai-Lechtich E; Shah K
Int J Mol Med; 2021 Jul; 48(1):. PubMed ID: 34080646
[TBL] [Abstract][Full Text] [Related]
2. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing TRAIL‑resistant A549 lung cancer cells and enhancing TRAIL‑induced apoptosis with the antidepressant amitriptyline.
Zinnah KMA; Park SY
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080659
[TBL] [Abstract][Full Text] [Related]
4. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
[TBL] [Abstract][Full Text] [Related]
6. IL13 Fused
Uludağ D; Karakaş N
Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
Horita H; Thorburn J; Frankel AE; Thorburn A
J Neurooncol; 2009 Nov; 95(2):175-184. PubMed ID: 19449148
[TBL] [Abstract][Full Text] [Related]
8. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation.
Zinnah KMA; Seol JW; Park SY
Int J Mol Med; 2020 Aug; 46(2):795-805. PubMed ID: 32626921
[TBL] [Abstract][Full Text] [Related]
10. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
11. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
Redjal N; Zhu Y; Shah K
Stem Cells; 2015 Jan; 33(1):101-10. PubMed ID: 25186100
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
14. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
15. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
16. Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
Park D; Ha IJ; Park SY; Choi M; Lim SL; Kim SH; Lee JH; Ahn KS; Yun M; Lee SG
J Nat Prod; 2016 Feb; 79(2):317-23. PubMed ID: 26829656
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
18. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
19. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
20. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]